#Germany #Fresenius Medical Care #Bad Homburg #Joseph Turk #Care Enablement

Joseph Turk to Lead Care Enablement at Fresenius Medical Care

Fresenius Medical Care (FME), renowned globally as a top provider for renal disease care, has announced the appointment of Joseph E. Turk as a Management Board Member, effective January 1, 2026. This strategic move comes as part of a planned transition for the company, with Turk set to take over the role of Chief Executive Officer for the Care Enablement global segment.

Turk's elevation comes at a crucial point for FME, marking a new chapter as he succeeds Dr. Katarzyna Mazur-Hofsäß, who has decided to retire by the end of this year. Under Mazur-Hofsäß's leadership since the inception of Care Enablement in 2022, the segment has made significant strides in enhancing support services for patients undergoing dialysis treatment - a domain where FME leads with a patient base of approximately 4.2 million worldwide.

Background of Joseph Turk

Joey Turk has been an integral part of Fresenius Medical Care since 2019, following the acquisition of NxStage Medical. His previous role as Executive Vice President of Global Home and Critical Care Therapies has positioned him well for this new responsibility. Turk boasts an impressive background with experience at major firms like Boston Scientific, McKinsey & Company, and Deloitte. His academic credentials include a master’s degree from the J.L. Kellogg Graduate School of Management at Northwestern University and an undergraduate degree in economics and chemistry from Wabash College.

Fresenius Medical Care’s Chairman of the Supervisory Board, Michael Sen, expressed confidence in Turk and highlighted the importance of his role in continuing the margin improvement track for Care Enablement. Michael Sen commended Turk’s experience and dedication, noting that he would be pivotal in rolling out the advanced 5008X CAREsystem to the U.S. market while spearheading innovations in patient care technology.

Additionally, Helen Giza, CEO and Chair of the Management Board, lauded Turk for his robust record and assured stakeholders of his seamless integration into the leadership team. Giza emphasized Turk's critical role in executing FME's Reignite strategy, which is central to driving forward the Care Enablement initiative.

A Smooth Transition and Future Direction

As Joseph Turk prepares to take the helm, he expressed enthusiasm about joining the management board at a time when the FME is focused on initiating revolutionary strategies aimed at enhancing care for patients. He reaffirmed his commitment to working collaboratively with committed employees across the globe to propel innovations that would benefit patients and caregivers alike.

The transition aims not only to maintain the momentum ushered in by Mazur-Hofsäß but also to explore new pathways for introducing groundbreaking technologies in treatment procedures, emphasizing the patient care experience. As Care Enablement continues to evolve, Turk's vision will be instrumental in meeting the ever-growing needs of the renal disease patient community.

Fresenius Medical Care operates a widespread network of over 3,676 dialysis clinics worldwide and serves roughly 300,000 patients with its life-saving dialysis treatments. As the company remains dedicated to providing high-quality renal care, the appointment of Joseph Turk symbolizes a commitment to innovation leadership and patient-centered healthcare solutions.

With the company's shares traded on both the Frankfurt Stock Exchange and the New York Stock Exchange, stakeholders and analysts will be keenly observing this phase of leadership change and the strategic decisions that will soon unfold under Turk’s guidance.

For further information about Fresenius Medical Care, visit their official website at www.freseniusmedicalcare.com.